Cheap Biotech Stocks To Buy -

: Trading at a forward P/E of approximately 9.27, which is significantly lower than its 5-year mean.

These companies are considered "cheap" due to low price-to-earnings (P/E) ratios relative to their historical averages or the broader sector.

These clinical-stage companies are often valued based on their pipelines and upcoming trial data readouts. cheap biotech stocks to buy

: A clinical-stage biotech developing heart disease therapies with positive Phase 2 data and a mean target price suggesting over 600% upside.

: Working on targeted radiotherapy; analysts project significant revenue growth in 2025-2026 if Phase 3 trials succeed. Undervalued Mid-to-Large Cap Leaders : Trading at a forward P/E of approximately 9

: A profitable firm trading at roughly 14 times earnings, well below the sector average of 26.

: A high-risk, high-reward mRNA play with major Phase 2 study results for cystic fibrosis expected in the first half of 2026. : A high-risk, high-reward mRNA play with major

: Trading at roughly 15 times earnings with double-digit increases in revenue and low debt.